Search PubMed⌕ Search

Biomedical subjects

H Sheardown

Publications and source records attributed to H Sheardown.

20 records · Page 2Linked to original sources

Fifty:fifty poly (DL glycolic acid-lactic acid) copolymer as a drug delivery system for 5-fluorouracil: a histopathological evaluation.

Fifty:fifty poly (DL glycolic acid-lactic acid) copolymer (PGLA) is a potentially useful depot drug delivery system for 5-fluorouracil (5-FU). The purpose of this study was to evaluate the fibroinflammatory reaction induced by this polymer. Polymer discs without 5-FU were inserted subconjunctivally in one eye of each of two guinea pigs and four pigmented rabbits (control group), and discs containing 20% 5-FU were inserted subconjunctivally in both eyes of nine pigmented rabbits (study group). The tissue reaction to the copolymer did not differ between rabbits and guinea pigs, with a mild mixed inflammatory reaction 1 week after implantation. At 2 weeks a thin fibrous capsule surrounded the discs, with no change in the amount of inflammation. At 4 weeks the disc had disintegrated, but residual polymer was seen within multinucleated giant cells in the episcleral tissue. Granulation tissue and inflammatory responses were mild. Less inflammation and fibrosis occurred in the study eyes, although the pattern of response was similar in the two groups. The inflammatory response to PGLA was markedly less than that to implanted collagen shields, and our findings suggest that PGLA implant is a promising ocular drug delivery system for 5-FU after filtration surgery.

Animals↗

Continuous epidermal growth factor delivery in corneal epithelial wound healing.

PURPOSE: To investigate the effects of a single prolonged exposure to recombinant epidermal growth factor on the healing of anterior keratotomy wounds in New Zealand white rabbits. METHODS: After wounding, eyes were perfused for 1, 2, 4, and 8 hours with either epidermal growth factor solution at a concentration of 50 micrograms/ml or balanced saline solution using a Morgan therapeutic lens (Mortan Inc, Missoula MT) and a syringe pump. Furthermore, concentration response was evaluated by perfusing with epidermal growth factor solutions at concentrations of 5, 50, 100 and 500 micrograms/ml for 4 hours. Wound healing rates were determined by quantitative morphometry of the wound area. The ratio of healing rates of eyes perfused with epidermal growth factor and control eyes provided a measure of the effect of epidermal growth factor on wound healing, and was defined as the epidermal growth factor enhancement factor. RESULTS: The enhancement factor was found to be 1.04 +/- 0.08, 1.17 +/- 0.07, 1.43 +/- 0.09, and 1.59 +/- 0.07 for perfusion times of 1, 2, 4, and 8 hours, respectively. The concentration response enhancement factors were 0.99 +/- 0.08, 1.43 +/- 0.09, 1.21 +/- 0.09, and 0.95 +/- 0.07 for the 5, 50, 100, and 500 micrograms/ml 4-hour perfusions, respectively. CONCLUSION: The results indicated that continuous epidermal growth factor exposures of as few as 2 hours produced a significant increase in healing rates (P < 0.05); increasing the time of exposure further increases the rate of wound healing. Results from the concentration response experiments showed that the optimum epidermal growth factor concentration for enhancing epithelial wound healing is approximately 50 micrograms/ml.

Animals↗